Lexeo Therapeutics, Inc. - Common Stock (LXEO)

Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.

The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss.

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

LXEO stock results show that Lexeo Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

The company is in the early stages of testing a gene therapy for the heart complications of a genetic disease.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Fastenal Company (NASDAQ: FAST) rose during Thursday’s session after the company reported better-than-expected quarterly financial results.

U.S. stocks traded higher, with the Dow Jones index gaining around 40 points on Tuesday. Here are some big stocks recording losses in today’s session.

Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the consensus of $1.532 billion. Adjusted EPS of 25 cents topped the street view of 23 cents.

Lexeo Therapeutics just reported results for the third quarter of 2023.

Shares of Pineapple Financial slipped over 25% in their trading debut following a downsized IPO. The tech-focused mortgage brokerage had cut the size of its offering from 1.25 million to 875,000 common shares at a price of $4 per share.